Davis Polk advised Citigroup Global Markets Inc., Jefferies & Company, Inc. and Morgan Stanley & Co. LLC as joint book-running managers in connection with a secondary offering of 24,150,000 ordinary shares of Alkermes plc, a public limited company incorporated under the laws of Ireland, held by a subsidiary of Elan Corporation plc for approximately $398.5 million. The ordinary shares are listed on the Nasdaq Global Market under the symbol “ALKS.”

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. 

The Davis Polk corporate team included partner Michael Kaplan and associates Sarah Whittington (admitted in DC only) and Roshni S. Banker (not yet admitted). The intellectual property team includes partner Frank J. Azzopardi and associates David R. Bauer, Pritesh P. Shah and Bruce Rose-Innes. Counsel Hayden S. Baker and associate Jesse Kramer provided environmental advice. Partner Samuel Dimon, associate Nessia Kushner and foreign temporary associate Johann Wagner provided tax advice. Katina D. Gallo was the legal assistant for the transaction. All members of the Davis Polk team are based in the New York office.